Clinical trials: Anthracycline-induced Cardiotoxicity
Cardiotoxicity, Breast Cancer
Dietary Restriction to Prevent Cardiotoxicity in Breast Cancer Patients
The goal of this clinical trial is to compare a dietary intervention with a regular diet in patients with early breast cancer undergoing anthracycline based chemotherapy.
- Trial name
- PROTECT-COR (NCT06622954)
- Testing
- Protein- and Calorie restriction
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Erasmus Medical Center
Anthracycline Induced Cardiotoxicity
Late Anthracycline Induced Cardiotoxicity- Childhood Cancer Survivors
Anthracyclines treat up to 60% of childhood malignancies with remarkable improvements survival rates. Unfortunately anthracyclines are associated with an increased cardiomyopathy risk.
- Trial name
- NCT04852965
- Where
- United Kingdom
- Volunteers
- 103 people
- Sponsor
- Queen's University, Belfast
Patients With Cancer
Ivabradine to Prevent Anthracycline-induced Cardiotoxicity
The aim of this study is to investigate protective effects of ivabradine in adult cancer patients undergoing anthracycline-based chemotherapy.
- Trial name
- NCT04030546
- Testing
- Ivabradine
- Where
- Lithuania
- Volunteers
- 128 people
- Sponsor
- Vilnius University
Doxorubicin Induced Cardiomyopathy
Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity
This study aims at evaluating the role of Atorvastatin in prevention of Anthracycline induced cardiotoxicity
- Trial name
- NCT05792293
- Testing
- Atorvastatin 40 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Anthracycline-induced Cardiotoxicity, Lymphoma
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
- Conditions
- Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, Cardiotoxicity
- Trial name
- SPARTACUS (NCT07572175)
- Testing
- Sotagliflozin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cancer
Prevention of Anthracycline-induced Cardiotoxicity
Anthracycline based anti-tumoral therapies are know to develop cardiac damage that could also lead to heart failure. Monocentric studies proved that a treatment with ACE inhibitors (ACEi) and betablockers (BB) during the first…
- Trial name
- ICOS-ONE (NCT01968200)
- Testing
- Enalapril
- Where
- Italy
- Volunteers
- 268 people
- Sponsor
- European Institute of Oncology
Cardiotoxicity, Cardiac Rehabilitation
Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity
This project aims to determine whether a comprehensive cardiac rehabilitation program including supervised exercise training is able to prevent cardiotoxicity during treatment with anthracyclines and / or anti-HER-2 antibodies in…
- Trial name
- ONCORE (NCT03964142)
- Testing
- Cardiac rehabilitation
- Where
- Spain
- Volunteers
- 122 people
- Sponsor
- Hospital Clinico Universitario de Santiago
Cancer, Cardiotoxicity
Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy
Over 50% of the more than 270,000 childhood cancer survivors in the U.S. have been treated with anthracyclines and thus are at risk of developing cardiotoxicity.
- Trial name
- NCT04036032
- Testing
- Exercise program
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Connecticut Children's Medical Center
Cardiac Dysfunction, Cardiovascular Diseases
Cardiac Dysfunction in Childhood Cancer Survivors
This multicenter, prospective cohort study evaluates early cardiac dysfunction in adult survivors of childhood cancer. The hypothesis of this study is that cardiac dysfunction can be detected earlier when using speckle tracking…
- Conditions
- Cardiac Dysfunction, Cardiovascular Diseases, Childhood Cancer
- Trial name
- Cardio-Onco (NCT03790943)
- Testing
- cardiac assessment
- Where
- 6 sites in Switzerland
- Volunteers
- 500 people
- Sponsor
- University of Bern
Cardiotoxicity
Remote Ischaemic Preconditioning in Childhood Cancer
Survival rates of children with cancers have improved significantly in the recent few decades. Nonetheless, the side effect of this class of drugs on heart function remains to be an issue of concern.
- Trial name
- NCT03166813
- Testing
- Remote Ischaemic Preconditioning, Control
- Where
- Hong Kong
- Volunteers
- 68 people
- Sponsor
- The University of Hong Kong
Anthracycline-induced Cardiac Toxicity, Lymphoma
REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs
Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic PreConditioning (RIPC) in Lymphoma patients receiving…
- Trial name
- RESILIENCE (NCT05223413)
- Testing
- RIPC
- Where
- 24 sites in Denmark, France and 4 more
- Volunteers
- 608 people
- Sponsor
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III
Breast Cancer
Cardiotoxicity of Cancer Therapy (CCT)
The objective of this study is to define the clinical significance of mechanistic biomarkers (including Neuregulin-1Beta) and novel echocardiographic measures of cardiac function in predicting the incident risk of cancer therapy…
- Trial name
- NCT01173341
- Testing
- Echocardiography, Blood Collection, Symptoms Questionnaire
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Childhood Cancer
Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity
Early microRNAs (miRs) and Cardiac Magnetic Resonance (CMR)-derived strain analysis and detection of genes contributing to Anthracycline-Induced Cardiotoxicity (AIC) sensitivity and resistance will identify pediatric cancer…
- Trial name
- NCT04036045
- Testing
- Cardiac MRI, Echocardiogram, Blood Draw
- Where
- United States
- Sponsor
- Connecticut Children's Medical Center
Breast Neoplasms, Cardiac Event
Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer
Totally 60 subjects will be included in the study. The present study was aimed to observe and evaluate the effect of Xinmailong injection on reducing cardiovascular toxicity associated with adjuvant chemotherapy after breast…
- Conditions
- Breast Neoplasms, Cardiac Event, Chemotherapeutic Toxicity
- Trial name
- NCT03785704
- Testing
- Xinmailong Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College
Breast Cancer
Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer
In the proposed project the investigators will asses whether changes in expression of selected circulating microRNAs in serum could comprise a sensitive and specific biomarker of cardiotoxicity in cancer patients treated with…
- Trial name
- NCT02065908
- Where
- 3 sites in Poland
- Volunteers
- 128 people
- Sponsor
- West Pomeranian Cancer Center
Early-stage Breast Cancer
Cardioprotective Effect of Acute Exercise in Breast Cancer Patients
Cardiotoxicity is one of the most significant adverse effects in breast cancer patients treated with anthracyclines (a type of chemotherapy), so we propose to determine whether acute training (i.e., 24h before each chemotherapy…
- Trial name
- CardioProtEx (NCT05467111)
- Testing
- Acute Exercise
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Technical University of Madrid
Anthracycline-induced Cardiotoxicity
Preventing Cardiac Sequelae in Pediatric Cancer Survivors
Cancer therapy can place childhood cancer survivors at increased risk for heart disease which can lead to significant illness or early death.
- Trial name
- PCS2 (NCT01805778)
- Where
- 6 sites in United States, Canada
- Volunteers
- 1,128 people
- Sponsor
- The Hospital for Sick Children
Breast Cancer
Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)
Consecutive patients with a first diagnosis of breast cancer will be identified at the Tom Baker Cancer Centre (TBCC) and included into the study, if they are going to receive chemotherapy with anthracyclines and / or Trastuzumab…
- Trial name
- Cardiotox (NCT00679874)
- Testing
- Cardio-vascular MRI
- Where
- Canada
- Volunteers
- 66 people
- Sponsor
- University of Calgary
Cardiac Toxicity, Unspecified Adult Solid Tumor, Protocol Specific
Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)
The goal of this clinical research study is to learn if certain biomarker testing on blood samples can help to detect heart damage that may occur during chemotherapy.
- Trial name
- NCT01032278
- Testing
- Laboratory Biomarker Analysis, Questionnaires
- Where
- 2 sites in United States
- Volunteers
- 597 people
- Sponsor
- M.D. Anderson Cancer Center
DLBCL - Diffuse Large B Cell Lymphoma
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity.
- Trial name
- HO170DLBCL (NCT06220032)
- Testing
- Dexrazoxane, Rituximab, Cyclophosphamide
- Where
- 25 sites in Netherlands
- Volunteers
- 324 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland